Publications dans lesquelles il/elle collabore avec Fernando Bandrés Moya (11)

2019

  1. Muscle Fitness Cut Points for Early Assessment of Cardiovascular Risk in Children and Adolescents

    Journal of Pediatrics, Vol. 206, pp. 134-141.e3

2017

  1. Cardiorespiratory Fitness Cutoff Points for Early Detection of Present and Future Cardiovascular Risk in Children: A 2-Year Follow-up Study

    Mayo Clinic Proceedings, Vol. 92, Núm. 12, pp. 1753-1762

  2. Convergent validation of a questionnaire to assess the mode and frequency of commuting to and from school

    Scandinavian Journal of Public Health, Vol. 45, Núm. 6, pp. 612-620

2016

  1. Inflammatory biomarkers and academic performance in youth. The UP & DOWN Study

    Brain, Behavior, and Immunity, Vol. 54, pp. 122-127

  2. Perceived environment in relation to objective and self-reported physical activity in Spanish youth. The UP&DOWN study

    Journal of Sports Sciences, Vol. 34, Núm. 15, pp. 1423-1429

2015

  1. Objectively measured and self-reported leisure-time sedentary behavior and academic performance in youth: The UP&DOWN Study

    Preventive Medicine, Vol. 77, pp. 106-111

2014

  1. Follow-up in healthy schoolchildren and in adolescents with DOWN syndrome: Psycho-environmental and genetic determinants of physical activity and its impact on fitness, cardiovascular diseases, inflammatory biomarkers and mental health; The UP&DOWN Study

    BMC Public Health, Vol. 14, Núm. 1

  2. Objective assessment of sedentary time and physical activity throughout the week in adolescents with Down syndrome: The UP&DOWN study

    Research in Developmental Disabilities, Vol. 35, Núm. 2, pp. 482-489

2010

  1. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants

    PLoS ONE, Vol. 5, Núm. 6

  2. CYP2D6 polymorphism screening in a selected population of Spain (La Alpujarra): No effect of geographical isolation

    Annals of Human Biology, Vol. 37, Núm. 2, pp. 267-273

2009

  1. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORCI c.-l 639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 591-593